Description: Idelalisib, also known as CAL-101, is a PI3K-delta inhibitor with potential immunomodulating and antineoplastic activities. CAL-101 inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and thus inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. CAL-101 has [EC(50)] = 8nM. TFA approved this drug on July 23, 2014. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (last updated: 2/23/2016)
Synonym: CAL101; CAL 101; CAL-101; GS1101; GS 1101; GS-1101, Idelalisib.
IUPAC/Chemical Name: (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
SMILES Code: O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
温馨提示:不可用于临床ZL。
资料下载:
GS-1101.gif
附件下载 (下载 0 次)
请 [登录] 后再下载!